Cancer Immunotherapy Awareness Month
To celebrate Cancer Immunotherapy Awareness Month this June, we are highlighting our researchers who have helped pioneer this research and continue to make seminal advances in this growing field. Dr. Steven Rosenberg was the first to demonstrate that an immunotherapy could cure certain patients with metastatic disease and he opened the doors to cell-based immunotherapies. He and his team continue to refine these approaches. Dr. Christian Hinrichs is researching cancer immunotherapy approaches to help patients with metastatic cancers caused by the human papilloma virus (HPV). Dr. Terry Fry and Dr. James Kochenderfer are focusing on genetically engineered T cells, called chimeric antigen receptor or CAR T cells, for the treatment of leukemia in children and the treatment of B-cell lymphomas and leukemias, respectively. Dr. James Gulley is studying the use of cancer vaccines and other immunostimulatory molecules to modify the immune system’s response in cancer patients. Drs. Jung-Min Lee, Jay Berzofsky, Andrea Apolo, Mark Gilbert, and Brigitte Widemann are actively pursuing checkpoint inhibitors, which can potentially increase a patient’s immune response to tumors. Dr. Thomas Waldmann, co-discovered a cytokine called IL-15, and has led the first-in-human clinical trial of this agent in patients with metastatic cancer. Dr. Ira Pastan pioneered the development of immunotoxins to treat cancer, including successful treatments for refractory hairy-cell leukemia. He and Dr. Raffit Hassan have recently made advances towards treating mesothelioma with immunotoxins. Many other CCR investigators are involved in immunotherapy research, explore our website to learn more.
Interested in our immunotherapy clinical trials currently open and enrolling? Click here